Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Invitrogen

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 20 March 1998:
Vol. 279. no. 5358, p. 1854
DOI: 10.1126/science.279.5358.1854
Prev | Table of Contents | Next

Research News

AIDS THERAPIES:
Exploring How to Get at--and Eradicate--Hidden HIV

Jon Cohen

DEDHAM, MASSACHUSETTS--The remarkable success achieved by various combinations of anti-HIV drugs has allowed researchers not only to think about whether the last bits of virus can be eliminated from the body, but also to speculate about how it might be done. The main obstacle is that even in people whose viral load is "undetectable," the virus continues to lurk in "latently" infected blood cells and in sites such as the brain, eyes, and testes. Although not everyone agrees that eradication is possible, researchers proposed several strategies at a recent conference, including injecting people with immune system messengers that could flush out the virus so that the patient's own immune system could pick it off and looking for ways to sneak drugs past borders such as the one that protects the brain.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Hydroxyurea and Interleukin-6 Synergistically Reactivate HIV-1 Replication in a Latently Infected Promonocytic Cell Line via SP1/SP3 Transcription Factors.
R. M. Oguariri, T. W. Brann, and T. Imamichi (2007)
J. Biol. Chem. 282, 3594-3604
   Abstract »    Full Text »    PDF »
New Anti-Human Immunodeficiency Virus Type 1 6-Aminoquinolones: Mechanism of Action.
C. Parolin, B. Gatto, C. Del Vecchio, T. Pecere, E. Tramontano, V. Cecchetti, A. Fravolini, S. Masiero, M. Palumbo, and G. Palu (2003)
Antimicrob. Agents Chemother. 47, 889-896
   Abstract »    Full Text »    PDF »
Synergistic Activation of Human Immunodeficiency Virus Type 1 Promoter Activity by NF-{kappa}B and Inhibitors of Deacetylases: Potential Perspectives for the Development of Therapeutic Strategies.
V. Quivy, E. Adam, Y. Collette, D. Demonte, A. Chariot, C. Vanhulle, B. Berkhout, R. Castellano, Y. de Launoit, A. Burny, et al. (2002)
J. Virol. 76, 11091-11103
   Abstract »    Full Text »    PDF »
Transport Characteristics of the Anti-human Immunodeficiency Virus Nucleoside Analog, Abacavir, into Brain and Cerebrospinal Fluid.
S. A. Thomas, A. Bye, and M. B. Segal (2001)
J. Pharmacol. Exp. Ther. 298, 947-953
   Abstract »    Full Text »
Viruses in the Mammalian Male Genital Tract and Their Effects on the Reproductive System.
N. Dejucq and B. Jegou (2001)
Microbiol. Mol. Biol. Rev. 65, 208-231
   Abstract »    Full Text »    PDF »
Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics.
C. M. Hogan and S. M. Hammer (2001)
Ann Intern Med 134, 978-996
   Abstract »    Full Text »    PDF »
Perivascular Macrophages Are the Primary Cell Type Productively Infected by Simian Immunodeficiency Virus in the Brains of Macaques: Implications for the Neuropathogenesis of AIDS.
K. C. Williams, S. Corey, S. V. Westmoreland, D. Pauley, H. Knight, C. deBakker, X. Alvarez, and A. A. Lackner (2001)
J. Exp. Med. 193, 905-916
   Abstract »    Full Text »    PDF »
Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease.
D. Serio, S. P. Singh, M. A. Cartas, I. T. Weber, R. W. Harrison, J. M. Louis, and A. Srinivasan (2000)
Protein Eng. Des. Sel. 13, 431-436
   Abstract »    Full Text »    PDF »
Latent reservoirs of HIV: Obstacles to the eradication of virus.
T.-W. Chun and A. S. Fauci (1999)
PNAS 96, 10958-10961
   Full Text »    PDF »
Microglia Express CCR5, CXCR4, and CCR3, but of These, CCR5 Is the Principal Coreceptor for Human Immunodeficiency Virus Type 1 Dementia Isolates.
A. V. Albright, J. T. C. Shieh, T. Itoh, B. Lee, D. Pleasure, M. J. O'Connor, R. W. Doms, and F. Gonzalez-Scarano (1999)
J. Virol. 73, 205-213
   Abstract »    Full Text »    PDF »
Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART.
E. A. Berger, B. Moss, and I. Pastan (1998)
PNAS 95, 11511-11513
   Abstract »    Full Text »    PDF »
A National Tissue Bank to Track HIV Eradication and Immune Reconstitution.
W. Cavert and A. T. Haase (1998)
Science 280, 1865-1866
   Abstract »    Full Text »
Toward HIV Eradication or Remission: The Tasks Ahead.
D. D. Ho (1998)
Science 280, 1866-1867
   Abstract »    Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)